TASQ

AcronymDefinition
TASQTemplate-Assembled Synthetic G-Quartet
TASQTotal Annual Storage Quantity (gas storage)
TASQTransparent Auto-Switch Quality (Quitum Technologies)
TASQTransgenic Animal Service of Queensland (Australia)
TASQTactical Airlift Squadron
References in periodicals archive ?
The trial's main objective is to determine the recommended dose of TASQ in combination with cabazitaxel based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).
At present, a global, pivotal, randomised, double-blind, placebo-controlled Phase III study of TASQ in patients with metastatic CRPC is being implemented with the aim of confirming the agent's effect on the disease.
In April, Active Biotech announced an agreement with France-based sector player Ipsen SA (EPA: IPN) to co-develop and commercialise prostate cancer drug candidate Tasq (tasquinimod).
In April, Active Biotech unveiled an agreement with French Ipsen SA (EPA: IPN) to co-develop and commercialise Tasq (tasquinimod).
Active Biotech has granted Ipsen exclusive worldwide marketing rights to Tasq, while retaining the rights for the Americas and Japan.
In 2009, Active Biotech fully enrolled three large clinical studies, obtained proof-of-concept for the TASQ project, andpublished a first target molecule for the ISI project, CEO Tomas Leanderson said.
The higher R&D costs were due to the ongoing Phase III trial for the ANYARA renal cancer project, the ongoing Phase II trial for the TASQ prostate cancer project and the 57-57 project for the treatment of systemic lupus erythematosus (SLE).
NORDIC BUSINESS REPORT-7 June 2010-Active Biotech presents phase II data with TASQ at ASCO(C)1994-2010 M2 COMMUNICATIONS http://www.m2.com
M2 EQUITYBITES-7 June 2010-Active Biotech presents phase II data with TASQ at ASCO(C)2010 M2 COMMUNICATIONS http://www.m2.com
Biotechnology company Active Biotech AB (NASDAQ OMX Nordic:ACTI) said on Monday that it has reached the primary endpoint in the company's ongoing Phase II clinical study of TASQ in patients with asymptomatic, castrate resistant, metastatic prostate cancer.
14 December 2009 - Swedish biotechnology company Active Biotech AB (STO: ACTI) said that its drug candidate TASQ reached its primary endpoint to show a difference in the number of patients with disease progression at six months in the ongoing Phase II study in patients with prostate cancer, according to analysis on data from at least six months' treatment of more than 200 patients.
NORDIC BUSINESS REPORT-25 September 2009-Active Biotech says Tasq prostate cancer drug featured in British journal(C)1994-2009 M2 COMMUNICATIONS http://www.m2.com